MedTrace Logo

Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients

NCT02290210 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2017-03-08

No results posted yet for this study

Summary

The purpose of this study is to assess safety, PK/PD and Urate Lowering Effect of URC102 in gout patients with hyperuricemia

Conditions

  • Gout
  • Hyperuricemia

Interventions

DRUG

URC102 0.25mg

DRUG

URC102 0.5mg

DRUG

URC102 1.0mg

DRUG

URC102 2.0mg

DRUG

placebo

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-24
Primary Completion
2014-12-02
Completion
2015-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02290210 on ClinicalTrials.gov